Sökning: WFRF:(Goemans N) >
Long-Term Efficacy,...
-
Goemans, N. M.
(författare)
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
-
2016-09-02
-
Public Library of Science (PLoS),2016
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/243593
-
https://gup.ub.gu.se/publication/243593URI
-
https://doi.org/10.1371/journal.pone.0161955DOI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background Drisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations. This 188-week open-label extension of the dose-escalation study assessed the long-term efficacy, safety, and pharmacokinetics of drisapersen (PRO051/GSK2402968), 6 mg/kg subcutaneously, in 12 DMD subjects. Dosing was once weekly for 72 weeks. All subjects had a planned treatment interruption (weeks 73-80), followed by intermittent dosing (weeks 81-188). Subjects received a median (range) total dose of 5.93 (5.10 to 6.02) mg/kg drisapersen. After 177 weeks (last efficacy assessment), median (mean [SD]) six-minute walk distance (6MWD) improved by 8 (-24.5 [161]) meters for the 10 subjects able to complete the 6MWD at baseline (mean age [SD]: 9.5 [1.9] years). These statistics include 2 subjects unable to complete the test at later visits and who scored "zero". When only the 8 ambulant subjects at week 177 were taken into account, a median (mean [SD]) increase of 64 (33 [121]) meters in 6MWD was observed. Of 7 subjects walking >= 330 m at extension baseline, 5 walked farther at week 177. Of 3 subjects walking <330 m, 2 lost ambulation, while 1 declined overall but walked farther at some visits. Over the 188 weeks, the most common adverse events were injection-site reactions, raised urinary alpha(1)-microglobulin and proteinuria. Dystrophin expression was detected in all muscle biopsies obtained at week 68 or 72. Drisapersen was generally well tolerated over 188 weeks. Possible renal effects, thrombocytopenia and injection-site reactions warrant continued monitoring. Improvements in the 6MWD at 12 weeks were sustained after 3.4 years of dosing for most patients. For a small, uncontrolled study, the outcomes are encouraging, as natural history studies would anticipate a decline of over 100 meters over a 3-year period in a comparable cohort.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Tulinius, Mar,1953Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics(Swepub:gu)xtulim
(författare)
-
van den Hauwe, M.
(författare)
-
Kroksmark, Anna-KarinGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics(Swepub:gu)xkrann
(författare)
-
Buyse, G.
(författare)
-
Wilson, R. J.
(författare)
-
van Deutekom, J. C.
(författare)
-
de Kimpe, S. J.
(författare)
-
Lourbakos, A.
(författare)
-
Campion, G.
(författare)
-
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för pediatrik
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Plos One: Public Library of Science (PLoS)11:91932-6203
Internetlänk
Hitta via bibliotek
-
Plos One
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Goemans, N. M.
-
Tulinius, Mar, 1 ...
-
van den Hauwe, M ...
-
Kroksmark, Anna- ...
-
Buyse, G.
-
Wilson, R. J.
-
visa fler...
-
van Deutekom, J. ...
-
de Kimpe, S. J.
-
Lourbakos, A.
-
Campion, G.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Plos One
- Av lärosätet
-
Göteborgs universitet